Vor Biopharma Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Vor Biopharma Inc. (VOR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $9.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $9.40M, a 409.71% increase year-over-year.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.87M, a 358.87% increase year-over-year.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.03M, a 254.64% increase year-over-year.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.84M, a 33.98% decline year-over-year.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $18.91M, a 92.06% increase from fiscal 2024.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $9.85M, a 26.31% decline from fiscal 2023.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $13.36M, a 24.94% increase from fiscal 2022.
- Vor Biopharma Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.70M, a 147.91% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.40M 10-Q · filed 2026-08-11 | $18.27M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $8.87M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $18.91M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $8.03M 10-Q · filed 2025-11-13 | $9.87M derived: sum of 2 quarters · filed 2026-08-11 | $11.81M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.84M 10-Q · filed 2026-08-11 | $3.78M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $1.93M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $9.85M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $2.26M 10-Q · filed 2025-11-13 | $5.06M derived: sum of 2 quarters · filed 2025-11-13 | $8.14M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $2.79M 10-Q · filed 2025-11-13 | $5.87M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $3.08M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $13.36M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $3.16M 10-Q · filed 2024-11-07 | $7.40M derived: sum of 2 quarters · filed 2024-11-07 | $11.47M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $4.24M 10-Q · filed 2024-11-07 | $8.31M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $4.07M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $10.70M 10-K · filed 2024-03-20 | |||
| 2022-09-30 | $3.33M 10-Q · filed 2023-11-07 | $5.07M derived: sum of 2 quarters · filed 2023-11-07 | $6.82M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $1.74M 10-Q · filed 2023-11-07 | $3.49M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $1.75M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $4.31M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $1.15M 10-Q · filed 2022-11-10 | $2.22M derived: sum of 2 quarters · filed 2022-11-10 | $3.11M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.07M 10-Q · filed 2022-11-10 | $1.96M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $891.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $1.34M 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $483.00K 10-Q · filed 2021-11-10 | $636.00K derived: sum of 2 quarters · filed 2021-11-10 | $748.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $153.00K 10-Q · filed 2021-11-10 | $265.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $112.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |